New drug candidate takes on Hard-to-Treat myeloma
NCT ID NCT04000282
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-stage trial tested an experimental drug called SAR442085 in 37 people with multiple myeloma that had returned or stopped responding to prior treatments. The main goals were to find a safe dose and check for any signs that the drug shrinks tumors. Participants received the drug by IV infusion, and researchers monitored side effects and how the drug moved through the body.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SAR442085 (an experimental drug given by IV infusion)
What this could lead to
If successful, this could lead to a new treatment option for people with multiple myeloma that has stopped responding to other therapies.
What could go wrong
This is a very early Phase 1 trial with only 37 people, so it is primarily testing safety and dosing. The drug may not work well or could have serious side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLASMA CELL MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Site Number : 8400002
Duarte, California, 91010, United States
-
Dana Farber Cancer Institute Site Number : 8400003
Boston, Massachusetts, 02115, United States
-
Froedtert Hospital & Medical College of Wisconsin Site Number : 8400004
Milwaukee, Wisconsin, 53226, United States
-
Investigational Site Number : 1580001
Taipei, 10002, Taiwan
-
Investigational Site Number : 2030001
Prague, 12808, Czechia
-
Investigational Site Number : 2030002
Brno, 62500, Czechia
-
Investigational Site Number : 2030003
Ostrava - Poruba, 70852, Czechia
-
Investigational Site Number : 2500001
Toulouse, 31059, France
-
Investigational Site Number : 3000001
Athens, 11528, Greece
-
Investigational Site Number : 7240001
Salamanca, Salamanca, 37007, Spain
-
Mayo Clinic of Rochester Site Number : 8400005
Rochester, Minnesota, 55905, United States
-
UNC Chapel Hill Site Number : 8400006
Chapel Hill, North Carolina, 27599, United States